2bind GmbH Relaunches with Renewed Focus on Empowering Drug Discovery through Biophysical Research Services
May 2017 – 2bind GmbH today announces a strategic relaunch, marking a significant milestone. The company underwent a transformative restructuring, setting the stage for its current position as a leading provider of biophysical research services. With the appointment of Dr. Thomas Schubert as CEO, 2bind sharpened its focus on delivering high-quality research services to support clients and customers in the biotech, pharmaceutical, and academic sectors. The company’s expertise in biophysical tools, techniques, and tailor-made assays empowers researchers to accelerate drug discovery and development across various stages, from hit identification to lead optimization. This strategic realignment also enabled 2bind to expand its portfolio of biophysical offerings, carefully selecting a broader range of tools and instruments to meet the diverse needs of its clients. This comprehensive approach ensures that researchers have access to the most cutting-edge technologies and expertise to drive their projects forward.
